Literature DB >> 31897203

Primary mesenchymal chondrosarcoma of the kidney without HEY1-NCOA2 and IRF2BP2-CDX1 fusion: A case report and review.

Atsushi Yamagishi1, Osamu Ichiyanagi2, Sei Naito1, Hiromi Ito1, Takanobu Kabasawa3, Mitsunori Yamakawa3, Norihiko Tsuchiya1.   

Abstract

Mesenchymal chondrosarcoma (MC) of the kidney is rare. To the best of our knowledge, the current report is the first case of a giant extraskeletal MC that arose primarily from the right kidney and mimicked renal cell carcinoma at the locally advanced stage (cT3bN0) with vena cava thrombus and multiple pulmonary arterial tumor emboli. Additionally, the literature on renal EMC is reviewed and the possibilities of oncogenic heterogeneity are discussed. A 64-year-old woman was admitted to Yamagata University Hospital for sudden onset of asymptomatic gross hematuria. CT revealed a 90 mm renal mass without calcification in the right kidney and tumor thrombus extending to the inferior vena cava. Radical nephrectomy with thrombectomy was performed. Lung metastasis was detected 2 months later. The patient received systemic chemotherapy, which was only marginally effective. She died of the malignancy 8 months after surgery. Microscopic examination of the tumor revealed typical histology of MC and a lack of HEY1-NCOA2 and IRF2BP2-CDX1 gene fusions in the tumor tissues. Not all MC patients may exhibit chromosomal alterations in the tumor, suggesting the presence of genetically heterogeneous pathways of MC oncogenesis. Further studies are required to confirm the present findings and reinforce the molecular diagnosis of MC. Copyright: © Yamagishi et al.

Entities:  

Keywords:  HEY1-NCOA2 fusion; IRF2BP2-CDX1 fusion; mesenchymal chondrosarcoma; tumor thrombus

Year:  2019        PMID: 31897203      PMCID: PMC6924144          DOI: 10.3892/ol.2019.11143

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


Introduction

Mesenchymal chondrosarcoma (MC) is a rare neoplasm and represents only 2 to 9% of all chondrosarcomas. Almost 24% of MCs originate from extraskeletal sites, such as head, neck, the extremities, and trunk. The kidney is an extremely rare origin of extraskeletal MC (EMC) (1). In a recent report from Japan (2), primary origins of MC were bone (58%) and soft tissues (42%). MC develops at various sites in the body, including the head and neck (12%), trunk (62%), and extremities (26%). The authors reported 5- and 10-year overall survival rates of 66 and 56%, respectively (2). In the absence of specific tumor markers and radiographic findings, the diagnosis of MC largely depends on pathologic examination (3,4). The HEY1-NCOA2 gene fusion is reported to be a specific chromosomal aberration for MC and may play a critical role in diagnosis due to its high sensitivity (3,5–7). Physiologically, HEY1 is considered to function mainly as a transcriptional repressor and NCOA2 encodes a transcriptional coactivator protein for intranuclear receptors (7). Recently, an IRF2BP2-CDX1 fusion gene was implicated as another candidate MC oncogene exclusive to the HEY1-NCOA2 fusion gene (8). We describe the first case of primary renal EMC mimicking renal cell carcinoma at the locally advanced stage (cT3bN0) accompanied by vena cava thrombus and multiple pulmonary tumor emboli. The microscopic pathology was typical of MC but the HEY1-NCOA2 and IRF2BP2-CDX1 gene fusions were not detected.

Case report

Clinical summary

A 64-year-old woman visited our clinic complaining of sudden onset asymptomatic gross hematuria and was hospitalized for further examination. Flank pain and fever were absent. Routine laboratory tests indicated no remarkable abnormality in hematology and urine cytology was negative. No past history was noted, except for liver cystectomy and right mastectomy. Computed tomography (CT) of the abdomen revealed a giant mass (90×70×67 mm) in the mid to lower pole of the right kidney. The tumor was hypovascular on contrast-enhanced CT images compared with adjacent normal renal parenchyma, although tumor vessels surrounding the mass were well-developed. In addition, the tumor was characterized as internally heterogeneous, free of calcification, and protruding into the inferior vena cava (IVC) through the right renal vein to form a tumor thrombus up to the level of the caudate lobe of the liver (Fig. 1). Tumor emboli were disseminated to pulmonary arteries, but no distant metastases were identified. The tumor presented with a high standardized uptake value of 12.00 at the maximum in positron emission tomography (PET)-CT. Magnetic resonance imaging (MRI) with delayed contrast-enhancement revealed the heterogeneous nature of the tumor. On plain MRI, the tumor had high, low, slightly low, and slightly low signal intensities on T2-weighted, T1-weighted, diffusion-weighted, and apparent diffusion coefficient mapping images, respectively. Histological examination using percutaneous needle-biopsied specimens of the tumor revealed that it contained atypical chondrocytes and spindle cells with high nuclear-to-cytoplasmic ratio, suggesting renal chondrosarcoma. Radical nephrectomy with intracaval thrombectomy was performed for the initial treatment for the tumor. We successfully en bloc resected the whole kidney and the attached IVC thrombus using an artificial heart-lung machine and clamping IVC just beneath the beginning of the hepatic veins in cooperation with vascular surgeons.
Figure 1.

Abdominal computed tomography scan. (A) Plain computed tomography did not reveal calcification in the tumor. (B) The tumor was marginally enhanced and was heterogeneous. (C) The tumor thrombus extended into the IVC and reached the level of the caudal lobe of the liver. The right lobe of the liver had been previously resected. IVC, inferior vena cava.

The results of the pathological investigation of the resected specimens are presented in Fig. 2. They had biphasic morphological components with transition zones between round and spindle-shaped hyperchromic tumor cells and contained cartilaginous islands with good differentiation (Fig. 2A and B). The spindle-shaped cells showed indistinct cytoplasmic borders, inconspicuous nucleoli, and a hemangiopericytoma-like pattern (Fig. 2C). Tumor cells invaded into small lympho-vascular structures, renal veins, and renal hilar fat tissues. No metastasis was microscopically confirmed in any of the 11 local lymph nodes surgically resected in total, including para-aortic/vena cava and renal hilar lymph nodes. Immunohistochemically, the tumor was positively stained with antibodies to vimentin, CD99, and Ki-67 (labelling index: 60–70%), without immunoreaction to epithelial membrane antigen, CD34, chromogranin A, and synaptophysin. Expression of S-100 protein was negative in mesenchymal spindle cells, but was slightly positive only in some chondroid cells (Fig. 2D). Based on these pathological features, the tumor was diagnosed as primary renal EMC.
Figure 2.

Microscopic examination of the renal tumor. (A) Islands of well-differentiated cartilage surrounded by hyperchromic cells are visible in a hematoxylin and eosin stained section (magnification, ×40). (B) A transition zone was seen between cellular and cartilage components (arrow; hematoxylin and eosin; magnification, ×100). (C) A hemangiopericytoma-like pattern was seen (hematoxylin and eosin; magnification, ×200). (D) Immunoreaction to S-100 protein was positive in a cartilaginous island, but negative in the surrounding small tumor cells (magnification, ×100). This microphotograph shows the same region in (B).

Two months later, she experienced local recurrence and multiple lung metastases. Systemic chemotherapy was delivered and began with three courses of doxorubicin (30 mg/m2 on day 1–2, every 3 weeks). This was followed by pazopanib (800 mg/day), but the therapy was discontinued due to drug eruption at day 11. Eribulin mesilate was delivered in two courses (1.4 mg/m2 on day 1 and 8, every 3 weeks). The dose was reduced to 1.1 mg/m2 in the second cycle because of neutropenia. Palliative irradiation of 20 Gy was given to de novo metastasis to the right 8th rib for pain control. The patient's condition gradually worsened and she finally died of the malignancy 8 months after surgery.

HEY1-NCOA2 and IRF2BP2-CDX1 gene fusion

Standard reverse transcription-polymerase chain reaction (RT-PCR) were used to detect the HEY1-NCOA2 and IRF2BP2-CDX1 chromosomal fusions, as described elsewhere (9). In brief, RNA samples were extracted from surgically resected and fleshly frozen MC tissues with mirVana™ miRNA Isolation kit (Life Technologies). Total RNA (2 µg) was reverse-transcribed in a 20 µl reaction volume using a cDNA Reverse Transcription Kit according to the manufacturer's instructions (Applied Biosystems). RT-PCR was run using 1 µl cDNA in a 50 µl PCR reaction using AmpliTaq Gold DNA polymerase (Applied Biosystems). Primers for HEY1-NCOA2 fusion, STAU2, and ZFHX4 are shown in Table I and Fig. 3A (all were purchased from Integrated DNA Technologies, IA, USA). The primers for IRF2BP2-CDX1 were the same as reported previously (Integrated DNA Technologies) (8). The PCR conditions were 95°C for 30 sec, 55–60°C (according to the Tm of each primer provided from the manufacturer) for 30 sec, and 72°C for 45 sec after initial denaturation at 95°C for 2 min. Thirty-five cycles were run. RT-PCR of the housekeeping gene encoding β-actin was run on all samples to check the RNA quality. PCR products were checked using 2% agarose gel electrophoresis.
Table I.

Primer sequences for PCR.

Primer5′→3′
HEY1_F1CGAGGTGGAGAAGGAGAGTG
HEY1_F2ACCGGATCAATAACAGTTTG
HEY1_RCCCGAAATCCCAAACTCCGA
NCOA2_FAGCTTTTCCCAGACACGAGG
NCOA2_R1TCCTGGCTGAGGTATCAC
NCOA2_R2AGTTGGGCTTTGCAATGTGA
STAU2_FACTCCCCCTTGTTCTCCAGT
STAU2_RTGCCTGGTTATTGTCCGCTT
ZFHX4_FCCGCTGATGACTGGACAACT
ZFHX4_RGGTGTTGGTCTTCACCGCTA
βActin_FCCTCGCCTTTGCCGATCC
βActin_RGGATCTTCATGAGGTAGTCAGTC
IRF2BP2_F1CAAGAGCCGCGGGTCTGGAGA
IRF2BP2_F2GTCAACAGGCCCAAGACCGTGC
IRF2BP2_RGTGTGGTCCGGTTGGAATGAGGTG
CDX1_FCCGCAGTACCCCGACTTCTCCAG
CDX1_R1GTTCAGTGAGCCCCAGATTGGCAG
CDX1_R2TGATGTCGTGGGCCATCGGC
Figure 3.

RT-PCR analysis of the HEY1-NCOA2 fusion. (A) HEY1 and NCOA2 gene structures. The upper panel displays the wild type. HEY1 and NCOA2 genes are located on chromosome 8q. The STAU2 and ZFHX4 genes are located between them. The lower panel displays previously reported fusion genes. (B) Results of RT-PCR. The fusion gene was not detected. The actin band was clearly evident. Normal NCOA2, STAU2 and ZFX4F genes were detected. The results affirmed the absence of the fusion gene because those genes should be deleted if HEY1 and NCOA2 genes fuses at a certain breakpoint, and also indicated the success of RT-PCR. RT, reverse transcription; NCOA2, nuclear receptor coactivator 2; STAU2, staufen double-stranded RNA binding protein 2; ZFHX4, zinc finger homeobox 4; HEY1, hairy/enhancer-of-split related with YRPW motif 1.

The overall results of RT-PCR are presented in Fig. 3B. The HEY1-NCOA2 fusion gene was not observed in this patient. Instead of the fusion gene, intact HEY1 and NCOA2 genes were successfully detected. The presence of intact STAU2 and ZFHX4 genes, each of which should be deleted from the chromosome at the fusion of HEY1 and NCOA2 genes (Fig. 3A), was confirmed by RT-PCR in the patient's samples. Similarly, the IRF2BP2-CDX1 fusion was not detected in the patient (Fig. 4). Taken together, these findings demonstrate that the HEY1-NCOA2 and IRF2BP2-CDX1 gene fusions were absent or were not located at the chromosomal breakpoints that were previously reported.
Figure 4.

RT-PCR analysis of the IRF2BP2-CDX1 fusion. (A) IRF2BP2 and CDX1 gene structures. The upper panel displays the wild type. IRF2BP2 is located on chromosome 1q and CDX1 is located on chromosome 5q. The lower panel displays previously reported fusion genes. (B) Results of PCR. The IRF2BP2 and CDX1 gene fusion was not indicated, despite the presence of the actin band. Normal IRF2BP2 gene was detected as double bands reflecting its two isoforms. Normal CDX1 was difficult to detect with RT-PCR possibly due to GC richness in the CDX1 sequence. RT, reverse transcription; IRF2BP2, interferon regulatory factor 2 binding protein 2; CDX1, caudal type homeobox 1.

Discussion

Primary renal EMC is extremely rare (1). To our best knowledge, only 16 patients with renal EMC, including the present case, have been reported in the medical literature (Table II) (1,10–23). According to a review article on renal EMC (1), flank pain and hematuria are two most common clinical symptoms. Renal EMC occurs from children to elderly people with the peak incidence in the third decade, equally in men and women (1). No clinical differences in oncological behaviors are indicated between renal and non-renal origins of EMC (1). Despite a paucity of credible evidence for renal EMC, a favorable prognosis might be expected if the tumor is small, locally confined, and completely resected (1). Mimicking advanced renal cell carcinoma (cT3bN0), our case had tumor dissemination in pulmonary arteries at the initial presentation and early metastatic recurrence occurred in the bilateral lungs soon after radical nephrectomy with IVC thrombectomy.
Table II.

Case series about MC of the kidney.

No.YearAuthorAgeSexCalcificationSize (cm)Metastasis[a]TreatmentFollowOutcome
  11981Pitfield J61M+122 mDead
  21984Malhotra CM27M+9RTx, CTx, Mx69 mAlive
  31991Karanauskas S15M+ND+NDNDND
  42001Gomez-B52F+81 yAlive
  52006Kaneko T61F+2.56 yAlive
  62008Dantonello TM24FND10NAC1.3 yAlive
  72009Buse S23F+7+AC, RTx36 mAlive
  82012Xu H64M11+2 mDead
  92014Gherman V67M309 mDead
102014Tyagi R22F6.5+CTxNDAlive
112015Rothberg MB16F+15.2+NDNDND
122015Chen D17M15+[b]CTx10 mAlive
132017Salehipour M22M+9NDNDND
142017Pani K24M+8.5AC6 mAlive
152018Valente P35M+2018 mAlive
16Present case64F9CTx, RTx8 mDead

At the time of diagnosis.

Not proved pathologically. MC, mesenchymal chondrosarcoma; M, male; F, female; NAC, neoadjuvant chemotherapy; AC, adjuvant chemotherapy; CTx, chemotherapy; RTx, radiotherapy; Mx, metastasectomy; ND, no data; m, month; y, year.

MC is often difficult to diagnose because of the lack of specific findings. On clinical imaging, MC typically exhibits low CT attenuation with calcification and heterogeneous appearance, T1-low and T2-high/low intensities of MR signals, and strongly metabolic activity on PET-CT (4,24). These radiological findings are not specific to MC and its diagnosis entirely depends on histology. For this reason, MC is usually diagnosed with MC postoperatively. Renal MC is frequently misdiagnosed as renal cell carcinoma, renal pelvic cancer, or other rare malignant tumors, such as Wilms' tumor, in younger cases. In our case, the kidney tumor was initially suspected to be advanced RCC due to IVC thrombus and pulmonary tumor emboli. Low contrast-enhancement in CT and MRI and lack of remarkable findings of blood tests, including leukocyte and neutrophil counts, and serum levels of lactate dehydrogenase and C-reactive protein seem to be atypical for such advanced RCC. Percutaneous needle biopsy helped us to make an accurate pathological diagnosis and formulate sufficient treatment plans for the kidney tumor. However, not the all cases of MC could be successfully diagnosed with needle-biopsied specimens. Typically, MC histology shows a biphasic pattern, which consists of sheets of undifferentiated, round to spindle cell component, and islands of hyaline cartilage. The diagnosis in a small portion of biopsied tissues remains uncertain when the chondroid structures scattered within MC are not incidentally identified (3). This sampling error would be an intrinsic limitation in the histologic diagnosis of biopsied tissue. Chromosomal aberration of HEY1-NCOA2 fusion is reportedly specific to MC and can be a highly sensitive diagnostic tool (3,5,6). Table III presents 12 articles on the gene fusion in MC that were published in medical literature (3,5,6,8,25–32). The HEY1-NCOA2 gene fusion is supposed to be absent in another histologic type of sarcoma (3,5,6), but its diagnostic sensitivity is not perfect (67–100%) despite the characteristic histology of MC (Table III). Interestingly, the IRF2BP2-CDX1 gene fusion in MC may be exclusive to the HEY1-NCOA2 fusion, suggesting heterogeneous oncogenesis of MC (8,28). In the present study, we failed to detect the HEY1-NCOA2 and IRF2BP2-CDX1 gene fusions in renal EMC. Herein, CDX1 expression appeared to be absent in our case (Fig. 4). Specifically expressed in the intestines, CDX1 is a transcription factor to induce epithelial cell differentiation (33,34). In gastric, colorectal and hepatocellular carcinomas, CDX1 acts as a tumor suppressor and low expression of CDX1 are related clinically to poor prognosis of the malignancies (34). Thus, no expression of CDX1 might potentiate malignant nature in the present renal MC. Our results support the possible existence of another oncogenic mechanism in such fusion-negative cases, reflecting on the genetic heterogeneity in MC tumorigenesis to a typical microscopic phenotype.
Table III.

Case series about gene fusion of MC.

HEY1-NCOA2IRF2BP2-CDX1


YearAuthornPositivePositive ratio (%)nPositivePositive ratio (%)Assay
2012Wang L151067FISH, RT-PCR
2012Nyquist KB43754125FISH, RT-PCR
2012Nakayama R10880FISH
2013Fritchie KJ66100RT-PCR
2014Panagopoulos I11100RT-PCR
2014Andersson C11100RT-PCR
2014Moriya K11100FISH
2015Sajjad EA11100100RT-PCR
2015Bishop MW66100FISH
2016Cohen JN22100RT-PCR
2018Folpe AL33100RT-PCR
2018Toki S11100RT-PCR
Total5143845120

MC, mesenchymal chondrosarcoma; RT, reverse transcription; FISH, fluorescence in situ hybridization; NCOA2, nuclear receptor coactivator 2; IRF2BP2, interferon regulatory factor 2 binding protein 2; CDX1, caudal type homeobox 1.

It might be better to analyze HEY1, NCOA2, STAU2 and ZFHX4 gene expression using the adjacent or normal kidney tissues together with the renal MC for comparison (Fig. 3B). However, we were unable to do additional experiments due to the paucity of the freshly-frozen tissue samples left behind in store. This is a limitation in interpretation of the present results. In conclusion, we report the first case of primary renal EMC, which progressed to form tumor thrombus in IVC and pulmonary arteries at diagnosis. On pathological inspection of surgical specimens, the tumor exhibited typical microscopic appearance of MC. However, the presence of the HEY1-NCOA2 nor IRF2BP2-CDX1 gene fusions in the tumor was detected by RT-PCR, suggesting the possibility of genetically heterogeneous pathways to MC oncogenesis. Further studies will be needed to confirm the present findings and reinforce the molecular diagnosis of MC.
  34 in total

1.  Mesenchymal chondrosarcoma of the kidney.

Authors:  A Gomez-Brouchet; M Soulie; M B Delisle; G Escourrou
Journal:  J Urol       Date:  2001-12       Impact factor: 7.450

2.  Mesenchymal chondrosarcoma: clinicopathologic study of 20 cases.

Authors:  Rachel J Shakked; David S Geller; Richard Gorlick; Howard D Dorfman
Journal:  Arch Pathol Lab Med       Date:  2012-01       Impact factor: 5.534

3.  Minute mesenchymal chondrosarcoma within osteochondroma: an unexpected diagnosis confirmed by HEY1-NCOA2 fusion.

Authors:  Shunichi Toki; Toru Motoi; Mototaka Miyake; Eisuke Kobayashi; Akira Kawai; Akihiko Yoshida
Journal:  Hum Pathol       Date:  2018-03-26       Impact factor: 3.466

4.  Mesenchymal chondrosarcomas showing immunohistochemical evidence of rhabdomyoblastic differentiation: a potential diagnostic pitfall.

Authors:  Andrew L Folpe; Rondell P Graham; Anthony Martinez; David Schembri-Wismayer; Jennifer Boland; Karen J Fritchie
Journal:  Hum Pathol       Date:  2018-03-17       Impact factor: 3.466

5.  Detection of HEY1-NCOA2 fusion by fluorescence in-situ hybridization in formalin-fixed paraffin-embedded tissues as a possible diagnostic tool for mesenchymal chondrosarcoma.

Authors:  Robert Nakayama; Yasuhiro Miura; Jiro Ogino; Michiro Susa; Itsuo Watanabe; Keisuke Horiuchi; Ukei Anazawa; Yoshiaki Toyama; Hideo Morioka; Makio Mukai; Tadashi Hasegawa
Journal:  Pathol Int       Date:  2012-12       Impact factor: 2.534

6.  Low CDX1 expression predicts a poor prognosis for hepatocellular carcinoma patients after hepatectomy.

Authors:  Hao Zheng; Yuan Yang; Meng-Chao Wang; Sheng-Xian Yuan; Tao Tian; Jun Han; Jun-Sheng Ni; Jian Wang; Hao Xing; Wei-Ping Zhou
Journal:  Surg Oncol       Date:  2016-05-24       Impact factor: 3.279

7.  Mesenchymal chondrosarcoma of soft tissues and bone in children, adolescents, and young adults: experiences of the CWS and COSS study groups.

Authors:  Tobias M Dantonello; Christoph Int-Veen; Ivo Leuschner; Andreas Schuck; Rhoikos Furtwaengler; Alexander Claviez; Dominik T Schneider; Thomas Klingebiel; Stefan S Bielack; Ewa Koscielniak
Journal:  Cancer       Date:  2008-06       Impact factor: 6.860

8.  Pancreatic involvement by mesenchymal chondrosarcoma harboring the HEY1-NCOA2 gene fusion.

Authors:  Jarish N Cohen; David A Solomon; Andrew E Horvai; Sanjay Kakar
Journal:  Hum Pathol       Date:  2016-08-18       Impact factor: 3.466

9.  Analysis of the human tissue-specific expression by genome-wide integration of transcriptomics and antibody-based proteomics.

Authors:  Linn Fagerberg; Björn M Hallström; Per Oksvold; Caroline Kampf; Dijana Djureinovic; Jacob Odeberg; Masato Habuka; Simin Tahmasebpoor; Angelika Danielsson; Karolina Edlund; Anna Asplund; Evelina Sjöstedt; Emma Lundberg; Cristina Al-Khalili Szigyarto; Marie Skogs; Jenny Ottosson Takanen; Holger Berling; Hanna Tegel; Jan Mulder; Peter Nilsson; Jochen M Schwenk; Cecilia Lindskog; Frida Danielsson; Adil Mardinoglu; Asa Sivertsson; Kalle von Feilitzen; Mattias Forsberg; Martin Zwahlen; IngMarie Olsson; Sanjay Navani; Mikael Huss; Jens Nielsen; Fredrik Ponten; Mathias Uhlén
Journal:  Mol Cell Proteomics       Date:  2013-12-05       Impact factor: 5.911

10.  Mesenchymal chondrosarcoma of the kidney.

Authors:  C M Malhotra; C H Doolittle; J V Rodil; M P Vezeridis
Journal:  Cancer       Date:  1984-12-01       Impact factor: 6.860

View more
  2 in total

Review 1.  Liquid Biopsy: A New Translational Diagnostic and Monitoring Tool for Musculoskeletal Tumors.

Authors:  Argyris C Hadjimichael; Alexandros Pergaris; Angelos Kaspiris; Athanasios F Foukas; Stamatios E Theocharis
Journal:  Int J Mol Sci       Date:  2021-10-26       Impact factor: 5.923

2.  Extraskeletal Mesenchymal Chondrosarcoma of the Uterus.

Authors:  Yurimi Lee; Sangjoon Choi; Hyun-Soo Kim
Journal:  Diagnostics (Basel)       Date:  2022-03-05
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.